{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:04:31Z","timestamp":1780668271850,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260481, 81860534, 82560042"],"award-info":[{"award-number":["82260481, 81860534, 82560042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"DOI":"10.1038\/s41435-026-00382-6","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:59:37Z","timestamp":1773154777000},"page":"289-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory mechanisms of ALKBH5\/CIITA axis in the synergistic modulation of hepatocellular carcinoma radiotherapy and immunotherapy"],"prefix":"10.1038","volume":"27","author":[{"given":"Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongdan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-8460","authenticated-orcid":false,"given":"Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"382_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"382_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","volume":"64","author":"M Sayiner","year":"2019","unstructured":"Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci. 2019;64:910\u20137.","journal-title":"Dig Dis Sci"},{"key":"382_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037\u201348.","journal-title":"Cancer Commun (Lond)"},{"key":"382_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/JHC.S61146","volume":"3","author":"J Balogh","year":"2016","unstructured":"Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M Saharia A, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41\u201353.","journal-title":"J Hepatocell Carcinoma"},{"key":"382_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41416-021-01453-3","volume":"126","author":"G Zhou","year":"2022","unstructured":"Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer. 2022;126:10\u201323.","journal-title":"Br J Cancer"},{"key":"382_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","volume":"28","author":"JC Lee","year":"2022","unstructured":"Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. The liver-immunity nexus and cancer immunotherapy. Clin Cancer Res. 2022;28:5\u201312.","journal-title":"Clin Cancer Res"},{"key":"382_CR7","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet"},{"key":"382_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"382_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21:571\u201380.","journal-title":"Lancet Oncol"},{"key":"382_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618206","volume":"11","author":"J Mei","year":"2021","unstructured":"Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol. 2021;11:618206.","journal-title":"Front Oncol"},{"key":"382_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568759","volume":"11","author":"YH Lee","year":"2020","unstructured":"Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond. Front Immunol. 2020;11:568759.","journal-title":"Front Immunol"},{"key":"382_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.radonc.2021.06.034","volume":"162","author":"Y Huang","year":"2021","unstructured":"Huang Y, Sheng H, Xiao Y, Hu W, Zhang Z, Chen Y, et al. Wnt\/\u03b2-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma. Radiother Oncol. 2021;162:34\u201344.","journal-title":"Radiother Oncol"},{"key":"382_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"382_CR14","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 1974;71:3971\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"382_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117\u201320.","journal-title":"Nature"},{"key":"382_CR16","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.celrep.2017.02.059","volume":"18","author":"Q Cui","year":"2017","unstructured":"Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, et al. m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 2017;18:2622\u201334.","journal-title":"Cell Rep"},{"key":"382_CR17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ni.3830","volume":"18","author":"Q Zheng","year":"2017","unstructured":"Zheng Q, Hou J, Zhou Y, Li Z, Cao X. The RNA helicase DDX46 inhibits innate immunity by entrapping m(6)A-demethylated antiviral transcripts in the nucleus. Nat Immunol. 2017;18:1094\u2013103.","journal-title":"Nat Immunol"},{"key":"382_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/onc.2017.351","volume":"37","author":"A Visvanathan","year":"2018","unstructured":"Visvanathan A, Patil V, Arora A, Hegde AS, Arivazhagan A, Santosh V, et al. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37:522\u201333.","journal-title":"Oncogene"},{"key":"382_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.omtn.2021.02.001","volume":"24","author":"H Li","year":"2021","unstructured":"Li H, Wu H, Wang Q, Ning S, Xu S, Pang D. Dual effects of N(6)-methyladenosine on cancer progression and immunotherapy. Mol Ther Nucleic Acids. 2021;24:25\u201339.","journal-title":"Mol Ther Nucleic Acids"},{"key":"382_CR20","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.21037\/atm-21-4712","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li L, Ye Z, Zhang L, Yao N, Gai L. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma. Ann Transl Med. 2021;9:1554.","journal-title":"Ann Transl Med"},{"key":"382_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670490","volume":"11","author":"G Yan","year":"2021","unstructured":"Yan G, An Y, Xu B, Wang N, Sun X, Sun M. Potential impact of ALKBH5 and YTHDF1 on tumor immunity in colon adenocarcinoma. Front Oncol. 2021;11:670490.","journal-title":"Front Oncol"},{"key":"382_CR22","doi-asserted-by":"publisher","first-page":"20159","DOI":"10.1073\/pnas.1918986117","volume":"117","author":"N Li","year":"2020","unstructured":"Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci USA. 2020;117:20159\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"382_CR23","doi-asserted-by":"publisher","first-page":"300060520951405","DOI":"10.1177\/0300060520951405","volume":"48","author":"P Mo","year":"2020","unstructured":"Mo P, Xie S, Cai W, Ruan J, Du Q, Ye J, et al. N(6)-methyladenosine (m(6)A) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules. J Int Med Res. 2020;48:300060520951405.","journal-title":"J Int Med Res"},{"key":"382_CR24","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","volume":"81","author":"X Qiu","year":"2021","unstructured":"Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, et al. M(6)A Demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res. 2021;81:4778\u201393.","journal-title":"Cancer Res"},{"key":"382_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/hep.31313","volume":"73","author":"GW Kim","year":"2021","unstructured":"Kim GW, Imam H, Khan M, Mir SA, Kim SJ, Yoon SK, et al. HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology. 2021;73:533\u201347.","journal-title":"Hepatology"},{"key":"382_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01239-w","volume":"19","author":"Y Chen","year":"2020","unstructured":"Chen Y, Zhao Y, Chen J, Peng C, Zhang Y, Tong R, et al. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m(6)A-guided epigenetic inhibition of LYPD1. Mol Cancer. 2020;19:123.","journal-title":"Mol Cancer"},{"key":"382_CR27","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1038\/s41388-020-1303-7","volume":"39","author":"C Zhang","year":"2020","unstructured":"Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020;39:4507\u201318.","journal-title":"Oncogene"},{"key":"382_CR28","doi-asserted-by":"crossref","unstructured":"Le\u00f3n Machado JA, Steimle V. The MHC Class II transactivator CIITA: Not (Quite) the odd-one-out anymore among NLR proteins. Int J Mol Sci. 2021;22:1074.","DOI":"10.3390\/ijms22031074"},{"key":"382_CR29","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/eji.200424964","volume":"34","author":"S LeibundGut-Landmann","year":"2004","unstructured":"LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol. 2004;34:1513\u201325.","journal-title":"Eur J Immunol"},{"key":"382_CR30","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.bcp.2011.05.026","volume":"82","author":"MC van Eggermond","year":"2011","unstructured":"van Eggermond MC, Boom DR, Klous P, Schooten E, Marquez VE, Wierda RJ, et al. Epigenetic regulation of CIITA expression in human T-cells. Biochem Pharmacol. 2011;82:1430\u20137.","journal-title":"Biochem Pharmacol"},{"key":"382_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41417-021-00302-y","volume":"29","author":"T Oda","year":"2022","unstructured":"Oda T, Nakamura R, Kasamatsu T, Gotoh N, Okuda K, Saitoh T, et al. DNA-double strand breaks enhance the expression of major histocompatibility complex class II through the ATM-NF-\u03ba\u0392-IRF1-CIITA pathway. Cancer Gene Ther. 2022;29:225\u201340.","journal-title":"Cancer Gene Ther"},{"key":"382_CR32","first-page":"1549","volume":"14","author":"L Zhang","year":"2021","unstructured":"Zhang L, Luo Y, Cheng T, Chen J, Yang H, Wen X, et al. Development and validation of a prognostic N6-methyladenosine-related immune gene signature for lung adenocarcinoma. Pharmgenom Pers Med. 2021;14:1549\u201363.","journal-title":"Pharmgenom Pers Med"},{"key":"382_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152666","volume":"215","author":"T Xia","year":"2019","unstructured":"Xia T, Wu X, Cao M, Zhang P, Shi G, Zhang J, et al. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Pathol Res Pract. 2019;215:152666.","journal-title":"Pathol Res Pract"},{"key":"382_CR34","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.4049\/jimmunol.180.3.1826","volume":"180","author":"KC Tang","year":"2008","unstructured":"Tang KC, Trzaska KA, Smirnov SV, Kotenko SV, Schwander SK, Ellner JJ, et al. Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA. J Immunol. 2008;180:1826\u201333.","journal-title":"J Immunol"},{"key":"382_CR35","doi-asserted-by":"crossref","unstructured":"Forlani G, Shallak M, Celesti F, Accolla RS. Unveiling the hidden treasury: CIITA-driven MHC class II expression in tumor cells to dig up the relevant repertoire of tumor antigens for optimal stimulation of tumor specific CD4+ T helper cells. Cancers (Basel). 2020;12:3181.","DOI":"10.3390\/cancers12113181"},{"key":"382_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.4049\/jimmunol.1900778","volume":"204","author":"AM Johnson","year":"2020","unstructured":"Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, et al. Cancer cell-intrinsic expression of MHC class II regulates the immune microenvironment and response to anti-PD-1 therapy in lung adenocarcinoma. J Immunol. 2020;204:2295\u2013307.","journal-title":"J Immunol"},{"key":"382_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35069-0","volume":"8","author":"S Patel","year":"2018","unstructured":"Patel S, Waghela B, Shah K, Vaidya F, Mirza S, Patel S, et al. Silibinin, A natural blend in polytherapy formulation for targeting Cd44v6 expressing colon cancer stem cells. Sci Rep. 2018;8:16985.","journal-title":"Sci Rep"},{"key":"382_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/1878-0261.12647","volume":"14","author":"HT Lai","year":"2020","unstructured":"Lai HT, Chiang CT, Tseng WK, Chao TC, Su Y. GATA6 enhances the stemness of human colon cancer cells by creating a metabolic symbiosis through upregulating LRH-1 expression. Mol Oncol. 2020;14:1327\u201347.","journal-title":"Mol Oncol"},{"key":"382_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1028600","volume":"12","author":"H Yin","year":"2022","unstructured":"Yin H, Fu X, Gao H, Gao H, Ma Y, Chen X, et al. Hybrid peptide NTP-217 triggers ROS-mediated rapid necrosis in liver cancer cells by induction of mitochondrial leakage. Front Oncol. 2022;12:1028600.","journal-title":"Front Oncol"},{"key":"382_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-022-02428-9","volume":"41","author":"F Fang","year":"2022","unstructured":"Fang F, Lu J, Sang X, Tao YF, Wang JW, Zhang ZM, et al. Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia. J Exp Clin Cancer Res. 2022;41:225.","journal-title":"J Exp Clin Cancer Res"},{"key":"382_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23641-8","volume":"12","author":"VT Janmaat","year":"2021","unstructured":"Janmaat VT, Nesteruk K, Spaander MCW, Verhaar AP, Yu B, Silva RA, et al. HOXA13 in etiology and oncogenic potential of Barrett\u2019s esophagus. Nat Commun. 2021;12:3354.","journal-title":"Nat Commun"},{"key":"382_CR42","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013w102.","journal-title":"Nucleic Acids Res"},{"key":"382_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27521-y","volume":"8","author":"\u00c1 Nagy","year":"2018","unstructured":"Nagy \u00c1, L\u00e1nczky A, Menyh\u00e1rt O, Gy\u0151rffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8:9227.","journal-title":"Sci Rep"},{"key":"382_CR44","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.7150\/ijbs.70149","volume":"18","author":"Y You","year":"2022","unstructured":"You Y, Wen D, Zeng L, Lu J, Xiao X, Chen Y, et al. ALKBH5\/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression. Int J Biol Sci. 2022;18:5001\u201318.","journal-title":"Int J Biol Sci"},{"key":"382_CR45","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1136\/gutjnl-2014-307323","volume":"63","author":"G Giannelli","year":"2014","unstructured":"Giannelli G, Rani B, Dituri F, Cao Y, Palasciano G. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut. 2014;63:1668\u201376.","journal-title":"Gut"},{"key":"382_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626654","volume":"11","author":"W Zhu","year":"2021","unstructured":"Zhu W, Ru L, Ma Z. Identification of a novel four-gene signature correlated with the prognosis of patients with hepatocellular carcinoma: a comprehensive analysis. Front Oncol. 2021;11:626654.","journal-title":"Front Oncol"}],"container-title":["Genes &amp; Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00382-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:04:23Z","timestamp":1780664663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00382-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1038\/s41435-026-00382-6","relation":{},"ISSN":["1476-5470"],"issn-type":[{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal study has been approved by the Animal Research Committee at Mongolia Medical University, with ethical approval number YKD202002012, and all experimental protocols were conducted in accordance with institutional guidelines. The human study protocol was approved by the Ethical Committee of Medical Ethics Committee of Inner Mongolia Medical University (approval number YKD202201227), and informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}